MI-3
Modify Date: 2024-01-09 17:18:30
MI-3 structure
|
Common Name | MI-3 | ||
|---|---|---|---|---|
| CAS Number | 1271738-59-0 | Molecular Weight | 375.555 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 527.9±60.0 °C at 760 mmHg | |
| Molecular Formula | C18H25N5S2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 273.1±32.9 °C | |
Use of MI-3MI-3 is a Menin-MLL interaction inhibitor with IC50 value of 648 ± 25 nM.IC50 value: 648 ± 25 nM [1]Target: Menin-MLLin vitro: The menin-MLL inhibitors very effectively blocked proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI50 values of about 5 μM for MI-2 and MI-3. MI-2 and MI-3 showed only a small effect on the cell growth of E2A-HLF transduced BMC (GI50 > 50 μM). MI-2 and MI-3 substantially and specifically reduce the immortalization potential of cells transformed with MLL fusion oncoproteins [1].in vivo: MLL-AF9 transformed BMC that remained viable after 7 days of treatment with MI-2 and MI-3 showed substantial changes in morphology, indicative of monocytic differentiation, as evidenced by increased cell size, lower nuclear to cytoplasmic ratio and highly vacuolated cytoplasm. Consistent with the change in cell morphology, the expression of CD11b was substantially increased on MLL-AF9 transformed BMC after 7 days of treatment with MI-2 and MI-3 [1]. |
| Name | 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)piperazin-1-yl]-2-isopropyl-th ieno[2,3-d]pyrimidine |
|---|---|
| Synonym | More Synonyms |
| Description | MI-3 is a Menin-MLL interaction inhibitor with IC50 value of 648 ± 25 nM.IC50 value: 648 ± 25 nM [1]Target: Menin-MLLin vitro: The menin-MLL inhibitors very effectively blocked proliferation of MLL-AF9 and MLL-ENL transduced BMC, with GI50 values of about 5 μM for MI-2 and MI-3. MI-2 and MI-3 showed only a small effect on the cell growth of E2A-HLF transduced BMC (GI50 > 50 μM). MI-2 and MI-3 substantially and specifically reduce the immortalization potential of cells transformed with MLL fusion oncoproteins [1].in vivo: MLL-AF9 transformed BMC that remained viable after 7 days of treatment with MI-2 and MI-3 showed substantial changes in morphology, indicative of monocytic differentiation, as evidenced by increased cell size, lower nuclear to cytoplasmic ratio and highly vacuolated cytoplasm. Consistent with the change in cell morphology, the expression of CD11b was substantially increased on MLL-AF9 transformed BMC after 7 days of treatment with MI-2 and MI-3 [1]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 527.9±60.0 °C at 760 mmHg |
| Molecular Formula | C18H25N5S2 |
| Molecular Weight | 375.555 |
| Flash Point | 273.1±32.9 °C |
| Exact Mass | 375.155121 |
| PSA | 98.16000 |
| LogP | 3.23 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.713 |
| Storage condition | -20℃ |
| Water Solubility | Insuluble (4.5E-3 g/L) (25 ºC) |
| Thieno[2,3-d]pyrimidine, 4-[4-(4,5-dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-6-(1-methylethyl)- |
| 4-(4-(5,5-Dimethyl-4,5-dihydrothiazol-2-yl)piperazin-1-yl)-6-isopropylthieno[2,3-d]pyrimidine |
| 4-[4-(5,5-Dimethyl-4,5-dihydro-1,3-thiazol-2-yl)-1-piperazinyl]-6-isopropylthieno[2,3-d]pyrimidine |
| Thieno[2,3-d]pyrimidine, 4-[4-(4,5-dihydro-5,5-dimethyl-2-thiazolyl)-1-piperazinyl]-2-(1-methylethyl)- |
| 4-[4-(5,5-Dimethyl-4,5-dihydro-1,3-thiazol-2-yl)-1-piperazinyl]-2-isopropylthieno[2,3-d]pyrimidine |
| MI-3 (Menin-MLL Inhibitor) |
| MI-3 |